WO2019169143A1 - Compositions et méthodes de traitement du cancer à l'aide de t uricibacter sanguinis - Google Patents

Compositions et méthodes de traitement du cancer à l'aide de t uricibacter sanguinis Download PDF

Info

Publication number
WO2019169143A1
WO2019169143A1 PCT/US2019/020069 US2019020069W WO2019169143A1 WO 2019169143 A1 WO2019169143 A1 WO 2019169143A1 US 2019020069 W US2019020069 W US 2019020069W WO 2019169143 A1 WO2019169143 A1 WO 2019169143A1
Authority
WO
WIPO (PCT)
Prior art keywords
carcinoma
cancer
cell
turicibacter sanguinis
protein
Prior art date
Application number
PCT/US2019/020069
Other languages
English (en)
Inventor
Brian Goodman
Maria Sizova
Holly PONICHTERA
Peter SANDY
Original Assignee
Evelo Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences, Inc. filed Critical Evelo Biosciences, Inc.
Publication of WO2019169143A1 publication Critical patent/WO2019169143A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés et des compositions se rapportant à T uribacter sanguinis utile en tant qu'agent thérapeutique.
PCT/US2019/020069 2018-02-28 2019-02-28 Compositions et méthodes de traitement du cancer à l'aide de t uricibacter sanguinis WO2019169143A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636604P 2018-02-28 2018-02-28
US62/636,604 2018-02-28

Publications (1)

Publication Number Publication Date
WO2019169143A1 true WO2019169143A1 (fr) 2019-09-06

Family

ID=65991888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/020069 WO2019169143A1 (fr) 2018-02-28 2019-02-28 Compositions et méthodes de traitement du cancer à l'aide de t uricibacter sanguinis

Country Status (1)

Country Link
WO (1) WO2019169143A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3952864A4 (fr) * 2019-03-08 2023-05-10 The Regents of the University of California Compositions et procédés de modulation du métabolisme des lipides et des stéroïdes
WO2023247419A1 (fr) * 2022-06-22 2023-12-28 Société des Produits Nestlé S.A. Utilisation d'un agent de modulation du microbiote pour améliorer la formation osseuse et/ou la résistance osseuse

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
US8268798B2 (en) 2007-11-15 2012-09-18 Alcon Research, Ltd. Low density lipoprotein receptor-mediated siRNA delivery
US8283461B2 (en) 2004-03-05 2012-10-09 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
US8313772B2 (en) 2010-02-24 2012-11-20 Arrowhead Madison Inc. Compositions for targeted delivery of siRNA
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
US8426554B2 (en) 2010-12-29 2013-04-23 Arrowhead Madison Inc. In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
US20150232934A1 (en) * 2009-09-01 2015-08-20 Aeon Medix Inc. Extracellular vesicles derived from gram-positive bacteria, and use thereof
US20160022592A1 (en) 2013-03-14 2016-01-28 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2017091783A2 (fr) * 2015-11-24 2017-06-01 Seres Therapeutics, Inc. Compositions bactériennes synthétiques
US20170354697A1 (en) * 2016-06-14 2017-12-14 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
US8283461B2 (en) 2004-03-05 2012-10-09 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
US8268798B2 (en) 2007-11-15 2012-09-18 Alcon Research, Ltd. Low density lipoprotein receptor-mediated siRNA delivery
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
US20150232934A1 (en) * 2009-09-01 2015-08-20 Aeon Medix Inc. Extracellular vesicles derived from gram-positive bacteria, and use thereof
US8313772B2 (en) 2010-02-24 2012-11-20 Arrowhead Madison Inc. Compositions for targeted delivery of siRNA
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
US8426554B2 (en) 2010-12-29 2013-04-23 Arrowhead Madison Inc. In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
US20160022592A1 (en) 2013-03-14 2016-01-28 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2017091783A2 (fr) * 2015-11-24 2017-06-01 Seres Therapeutics, Inc. Compositions bactériennes synthétiques
US20170354697A1 (en) * 2016-06-14 2017-12-14 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection

Non-Patent Citations (45)

* Cited by examiner, † Cited by third party
Title
"Guide to Huge Computers", 1994, ACADEMIC PRESS
ACHTMAN M; WAGNER M: "Microbial diversity and the genetic nature of microbial species", NAT. REV. MICROBIOL., vol. 6, 2008, pages 431 - 440
ATSCHUL, S. F. ET AL., J MOLEC BIOL, vol. 215, 1990, pages 403
BERNSTEIN E ET AL.: "The rest is silence", RNA, vol. 7, 2002, pages 1509 - 1521, XP009010244
BHOOPALAM ET AL.: "Effect of dextran-S (alpha, 1-3 dextran) on the growth of plasmacytomas MOPC-104E and J558", J. IMMUNOL., vol. 125, no. 4, 1980, pages 1454 - 8
BOSSHARD P P ET AL: "Turicibacter sanguinis gen. nov., sp. nov., a novel anaerobic, Gram-positive bacterium", INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, GB, vol. 52, no. 4, 1 July 2002 (2002-07-01), pages 1263 - 1266, XP002615246, ISSN: 1466-5026, [retrieved on 20020118], DOI: 10.1099/IJS.0.02056-0 *
BRUMMELKAMP: "A system for stable expression of short interfering RNAs in mammalian cells", SCIENCE, vol. 296, 2002, pages 550 - 553, XP002626048, DOI: doi:10.1126/science.1068999
CAERS ET AL.: "Of mice and men: disease models of multiple myeloma", DRUG DISCOVERY TODAY: DISEASE MODELS, vol. 1, no. 4, 2004, pages 373 - 380, XP004698912, DOI: doi:10.1016/j.ddmod.2004.11.010
CARILLO ET AL., SIAM J APPLIED MATH, vol. 48, 1988, pages 1073
CHAI ET AL.: "Bioluminescent orthotopic model of pancreatic cancer progression", J. VIS. EXP., vol. 76, 2013, pages 50395
CLAESSON MJ; WANG Q; O'SULLIVAN O; GREENE-DINIZ R; COLE JR; ROSS RP; O'TOOLE PW: "Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions", NUCLEIC ACIDS RES, vol. 38, 2010, pages e200, XP055250083, DOI: doi:10.1093/nar/gkq873
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, no. I, 1984, pages 387
G. NORHEIM ET AL., PLOS ONE, vol. 10, no. 9, 2015, pages e0134353
GONZALEZ-CARMONA ET AL.: "CD40 ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo", HEPATOLOGY, vol. 48, no. 1, 2008, pages 157 - 168
GUO ET AL.: "Combinatorial Photothermal and Immuno Cancer Therapy Using Chitosan-Coated Hollow Copper Sulfide Nanoparticles", ASC NANO., vol. 8, no. 6, 2014, pages 5670 - 5681
HANAI ET AL., ANN NY ACAD SCI., vol. 1082, 2006, pages 9 - 17
HANNON, GJ: "RNA Interference", NATURE, vol. 418, 2002, pages 244 - 251, XP002979088, DOI: doi:10.1038/418244a
HOBB ET AL., EVALUATION OF PROCEDURES FOR OUTER MEMBRANE ISOLATION FROM CAMPYLOBACTER JEJUNI, vol. 155, 2009, pages 979 - 988
HOUOT ET AL.: "T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy", BLOOD, vol. 113, no. 15, 2009, pages 3546 - 3552, XP055097946, DOI: doi:10.1182/blood-2008-07-170274
HUTVAGNER G ET AL.: "RNAi: Nature abhors a double-strand", CURR. OPIN. GENETICS & DEVELOPMENT, vol. 12, pages 225 - 232, XP002329959, DOI: doi:10.1016/S0959-437X(02)00290-3
JY LEE ET AL., SCI REP., vol. 6, 6 May 2016 (2016-05-06), pages 25543
KAWATA ET AL., MOL CANCER THER., vol. 7, no. 9, 2008, pages 2904 - 12
KONSTANTINIDIS KT; RAMETTE A; TIEDJE JM: "The bacterial species definition in the genomic era", PHILOS TRANS R SOC LOND B BIOL SCI, vol. 361, 2006, pages 1929 - 1940
LATTANZIO ET AL.: "Defective Development of Pristane-Oil Induced Plasmacytomas in Interleukin-6-Deficient BALB/C Mice", AM. J. PATHOLOGY, vol. 151, no. 3, 1997, pages 689696
LEE NS; DOHJIMA T; BAUER G; LI H; LI M-J; EHSANI A; SALVATERRA P; ROSSI J: "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells", NATURE BIOTECHNOL., vol. 20, 2002, pages 500 - 505
LEEKHA ET AL.: "General Principles of Antimicrobial Therapy", MAYO CLIN PROC., vol. 86, no. 2, 2011, pages 156 - 167, XP055372896, DOI: doi:10.4065/mcp.2010.0639
MALETZKI ET AL.: "Pancreatic cancer regression by intratumoral injection of live streptococcus pyogenes in a syngeneic mouse model", GUT., vol. 57, 2008, pages 483 - 491
MINAKUCHI ET AL., NUCLEIC ACIDS RES., vol. 32, no. 13, 2004, pages e109
MIYAGISHI M; TAIRA K: "U6-promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells", NATURE BIOTECHNOL., vol. 20, 2002, pages 497 - 500, XP002961100, DOI: doi:10.1038/nbt0502-497
PADDISON PJ; CAUDY AA; BERNSTEIN E; HANNON GJ; CONKLIN DS: "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells", GENES & DEV., vol. 16, 2002, pages 948 - 958
PARTECKE ET AL.: "A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/B16 mouse using the Panc02 and 6606PDA cell lines", EUR. SURG. RES., vol. 47, no. 2, 2011, pages 98 - 107
PAUL CP; GOOD PD; WINER I; ENGELKE DR: "Effective expression of small interfering RNA in human cells", NATURE BIOTECHNOL., vol. 20, 2002, pages 505 - 508, XP001121066, DOI: doi:10.1038/nbt0502-505
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444
POTTER ET AL.: "Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens", J. NATL. CANCER INST., vol. 71, no. 2, 1983, pages 391 - 5
R.M. ATLAS: "Handbook of Microbiological Media", 2010, CRC PRESS
S. BIN PARK ET AL., PLOS ONE, vol. 6, no. 3, 2011, pages e17629
SAARELA ET AL., J. APPLIED MICROBIOLOGY, vol. 99, 2005, pages 1330 - 1339
SANDRINI ET AL.: "Fractionation by ultracentrifugation of gram negative cytoplasmic and membrane proteins", BIO-PROTOCOL., vol. 4, no. 21, 2014
SCHOLLER ET AL.: "Protoplast and cytoplasmic membrane preparations from Streptococcus sanguis and Streptococcus mutans", J GEN MICRO., vol. 129, 1983, pages 3271 - 3279
SUI G; SOOHOO C; AFFAR E-B; GAY F; SHI Y; FORRESTER WC; SHI Y: "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells", PROC. NATL. ACAD. SCI. USA, vol. 99, no. 6, 2002, pages 5515 - 5520, XP002964701, DOI: doi:10.1073/pnas.082117599
TAO ET AL., IMAGABLE 4T1 MODEL FOR THE STUDY OF LATE STAGE BREAST CANCER, vol. 8, 2008, pages 288
THEIN ET AL.: "Efficient subfractionation of gram-negative bacteria for proteomics studies", vol. 9, 2010, AM CHEM SOCIETY, pages: 6135 - 6147
WANG ET AL.: "IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4+ T cells and promoting CTL persistence in a murine model of plasmacytoma", ONCOLMMUNOLOGY, vol. 4, no. 7, 2015, pages e1014232 - 1,9
WANG ET AL.: "Systemic dissemination of viral vectors during intratumoral injection", MOLECULAR CANCER THERAPEUTICS, vol. 2, no. 11, 2003, XP003005068
YU J-Y; DERUITER SL; TURNER DL: "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells", PROC. NATL. ACAD. SCI. USA, vol. 99, no. 9, 2002, pages 6047 - 6052, XP002332096, DOI: doi:10.1073/pnas.092143499

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3952864A4 (fr) * 2019-03-08 2023-05-10 The Regents of the University of California Compositions et procédés de modulation du métabolisme des lipides et des stéroïdes
WO2023247419A1 (fr) * 2022-06-22 2023-12-28 Société des Produits Nestlé S.A. Utilisation d'un agent de modulation du microbiote pour améliorer la formation osseuse et/ou la résistance osseuse

Similar Documents

Publication Publication Date Title
US10576111B2 (en) Method of treating cancer using Bifidobacterium animalis ssp. lactis strain PTA-125097
US20190314427A1 (en) Methods of treating cancer using parabacteroides
US20210330718A1 (en) Composition and methods for treating cancer and immune disorders using veillonella bacteria
US10493113B2 (en) Compositions and methods for treating disease using a Blautia strain
WO2018112365A2 (fr) Procédés de traitement du cancer colorectal et d'un mélanome en utilisant parabacteroides goldsteinii
WO2018136598A1 (fr) Méthodes de traitement du cancer
EP3746121A1 (fr) Compositions et méthodes de traitement de troubles immunitaires à l'aide de bactéries lachnospiraceae
EP3570856A2 (fr) Méthodes de traitement du cancer
US11241461B2 (en) Treating cancer using a blautia strain
WO2019169181A1 (fr) Compositions et méthodes de traitement du cancer à l'aide de lactobacillus salivarius
WO2019178487A2 (fr) Compositions et méthodes de traitement d'une maladie à l'aide de klebsiella quasipneumoniae subsp. similipneumoniae
WO2019178490A1 (fr) Compositions et procédés pour traiter le cancer et l'inflammation utilisant klebsiella oxytoca
WO2019178055A1 (fr) Vésicules extracellulaires provenant de burkholderia
WO2021022110A1 (fr) Induction d'effets immunitaires à l'aide de bactéries du genre bifidobacterium
WO2019178494A1 (fr) Compositions et méthodes de traitement du cancer et de l'inflammation à l'aide de tyzzerella nexilis
WO2019178057A1 (fr) Procédés de traitement du cancer à l'aide de burkholderia
WO2019169143A1 (fr) Compositions et méthodes de traitement du cancer à l'aide de t uricibacter sanguinis
WO2019169160A1 (fr) Compositions et méthodes de traitement du cancer à l'aide de ruminococcus gnavus
WO2019169168A1 (fr) Compositions et méthodes de traitement du cancer à l'aide d'agathobaculum
WO2019169138A1 (fr) Compositions et méthodes de traitement du cancer à l'aide de paraclostridium benzoelyticum
WO2019075452A1 (fr) Identification de bactéries pour la cancérothérapie
WO2020006216A1 (fr) Compositions et méthodes de traitement du cancer faisant appel à des bactéries neisseria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19714509

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19714509

Country of ref document: EP

Kind code of ref document: A1